Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin

Executive Summary

Cempra Pharmaceuticals appears to be one of the first companies exploring the newly enacted “limited use” pathway for novel antibiotics. The company cited the approach as an option for fusidic acid for use against MRSA – but it sounds like it may also be on the table for the company’s recently rejected solithromycin.

Advertisement

Related Content

Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?
Antibiotic Pipeline Profile: Balancing Broad Spectrum And Limited Use
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options
Cempra Goes Back To The Future With New Product/Old Antibiotic Taksta
Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
FDA Prepares For LPAD: Orphan Drug Approvals Are Model

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel